13 completed, 1 recruiting, 1 terminated. 15 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 13, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Sumitomo Pharma Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP fH1 2 ug, fH1 8 ug, DSP-0546LP 2.5 ug - Influenza | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 144 | 2024-06-26 | 2026-04-17 |
| Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001) - PD - Parkinson's Disease | Phase 1 | Recruiting | University of California, San Diego | 7 | 2024-06-01 | 2026-08-17 |
| A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease DSP-9632P 27.5 mg, DSP-9632P 82.5 mg, Placebo - Levodopa-induced Dyskinesia, Parkinson's Disease | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 7 | 2022-05-31 | 2023-08-09 |
| Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia SEP-363856, Placebo - Schizophrenia | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 13 | 2020-03-31 | 2022-04-12 |
| A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia Alvocidib, Cytarabine, Mitoxantrone - Acute Myeloid Leukemia | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 10 | 2018-05-15 | 2022-04-12 |
| Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2). SEP-363856 - Schizophrenia | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 24 | 2017-11-29 | 2022-04-12 |
| Special Combination of BBI608 and Pembrolizumab Napabucasin, Pembrolizumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Takayuki Yoshino | 55 | 2016-10-01 | 2021-09-05 |
| A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas DSP-7888 - Glioblastoma, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Co., Ltd. | 18 | 2016-04-01 | 2022-04-12 |
| A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer BBI608, 5-FU, Irinotecan - Metastatic Colorectal Cancer | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 4 | 2015-12-01 | 2022-04-12 |
| Study of DSP-7888 in Patients With Myelodysplastic Syndrome DSP-7888 - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Co., Ltd. | 48 | 2015-05-01 | 2022-04-12 |
| A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma BBI503, Sorafenib - Advanced Solid Tumors, Hepatocellular Carcinoma | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 60 | 2015-03-01 | 2022-04-12 |
| A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma BBI608, Pemetrexed, Cisplatin - Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Co., Ltd. | 28 | 2015-02-01 | 2022-04-12 |
| A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma BBI608, Sorafenib - Hepatocellular Carcinoma | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 12 | 2015-02-01 | 2022-04-12 |
| Clinical Study of WT2725 in Patients With Advanced Malignancies WT2725 - Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 64 | 2012-07-31 | 2019-07-17 |
| DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season DSP-3025, Placebo - Allergic Rhinitis, Healthy Volunteer | Phase 1 | Completed | Sumitomo Pharma Co., Ltd. | 72 | 2009-06-01 | 2022-04-12 |
Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Parkinson Disease (2) · Schizophrenia (2) · Ataxia (1) · Brain Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Diseases (1) · Diffuse Intrinsic Pontine Glioma (1) · Dyskinesias (1) · Glioblastoma (1) · Glioma (1) · Influenza, Human (1) · Mesothelioma, Malignant (1)
napabucasin (4) · SEP-363856 (2) · Sorafenib (2) · Bevacizumab (1) · Cisplatin (1) · Cytarabine (1) · Daunorubicin (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Mitoxantrone (1) · Pemetrexed (1) · alvocidib (1) · pembrolizumab (1)
Japan (12) · United States (2) · Belgium (1)
Joseph Ciacci, MD (1) · Takayuki Yoshino, Dr (1)
PMID 34785698, PMID 35689544, PMID 37188895, PMID 42176363
2023 (1)